Central Nervous System
Central nervous system (CNS) diseases, including schizophrenia or Alzheimer’s disease, are a focus of Boehringer Ingelheim discovery research and development. We have a range of different compounds in development, some in advanced clinical phases. We specifically address cognitive impairment a problem across many neuropsychiatric diseases. Together with our research activity in other fields of psychiatry, including treatmentresistant depression and “beyond the pill” approaches, it represents our mission to develop effective innovative treatment approaches for these underserved illnesses.